An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma

References

• Thiagalingam S, Cheng K-H, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84–100.
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92(15):1210–1216.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–784.
   PubMed Web of Science ®Google Scholar
• Reeves R, Cserjesi P. Sodium butyrate induces new gene expression in Friend erythroleukemic cells. J Biol Chem. 1979;254(10):4283–4290.
   PubMed Web of Science ®Google Scholar
• Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets. 2005;9(4):809–824.
   PubMed Web of Science ®Google Scholar
• Watanabe T. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs. 2010;19(9):1113–1127.
   PubMed Web of Science ®Google Scholar
• Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res. 2012;116:199–237.
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280(29):26729–26734.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24):8567–8572.
   PubMed Web of Science ®Google Scholar
• Ververis K, Hiong A, Karagiannis TC, et al. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013;7:47–60.
   PubMedGoogle Scholar
• Gallo P, Latronico MV, Gallo P, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res. 2008;80(3):416–424.
   PubMed Web of Science ®Google Scholar
• Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest. 2003;112(6):863–871.
   PubMed Web of Science ®Google Scholar
• Saiyed ZM, Gandhi N, Agudelo M, et al. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int. 2011;58(6):656–664.
   PubMed Web of Science ®Google Scholar
• Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS. 2011;6(1):25–29.
   PubMed Web of Science ®Google Scholar
• Ylisastigui L, Archin NM, Lehrman G, et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. Aids. 2004;18(8):1101–1108.
   PubMed Web of Science ®Google Scholar
• Soragni E, Xu C, Cooper A, et al. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol. 2011;793:495–508.
   PubMedGoogle Scholar
• Mai A, Rotili D, Valente S, et al. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des. 2009;15(34):3940–3957.
   PubMed Web of Science ®Google Scholar
• Roger T, Lugrin J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune responses to toll-like receptor agonists and to infection. Blood. 2011;117(4):1205–1217.
   PubMed Web of Science ®Google Scholar
• Valenzuela-Fernandez A, Alvarez S, Gordon-Alonso M, et al. Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell. 2005;16(11):5445–5454.
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98(3):604–610.
   PubMed Web of Science ®Google Scholar
• Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and −3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90(1):15–23.
   PubMed Web of Science ®Google Scholar
• Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer. 2011;74(2):300–304.
   PubMed Web of Science ®Google Scholar
• Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004;112(1):26–32.
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14(6):1669–1677.
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139–148.
   PubMed Web of Science ®Google Scholar
• Rikimaru T, Taketomi A, Yamashita Y, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007;72(1–2):69–74.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420–5432.
   PubMed Web of Science ®Google Scholar
• Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, et al. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 2009;274(2):169–176.
   PubMed Web of Science ®Google Scholar
• Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 2005;24(28):4531–4539.
   PubMed Web of Science ®Google Scholar
• Marquard L, Gjerdrum LM, Christensen IJ, et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53(3):267–277.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391(6669):811–814.
   PubMed Web of Science ®Google Scholar
• Bhaskara S, Knutson SK, Jiang G, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18(5):436–447.
   PubMed Web of Science ®Google Scholar
• Heideman MR, Wilting RH, Yanover E, et al. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood. 2013;121(11):2038–2050.
   PubMed Web of Science ®Google Scholar
• Santoro F, Botrugno OA, Dal Zuffo R, et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood. 2013;121(17):3459–3468.
   PubMed Web of Science ®Google Scholar
• Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov. 2011;1(7):587–597.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15–23.
   PubMed Web of Science ®Google Scholar
• Vetting MW, De Carvalho LP, Yu M, et al. Structure and functions of the GNAT superfamily of acetyltransferases. Arch Biochem Biophys. 2005;433(1):212–226.
   PubMed Web of Science ®Google Scholar
• Guidez F, Howell L, Isalan M, et al. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol. 2005;25(13):5552–5566.
   PubMed Web of Science ®Google Scholar
• Kitabayashi I, Aikawa Y, Nguyen LA, et al. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. Embo J. 2001;20(24):7184–7196.
   PubMed Web of Science ®Google Scholar
• Katsumoto T, Aikawa Y, Iwama A, et al. MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev. 2006;20(10):1321–1330.
   PubMed Web of Science ®Google Scholar
• Pelletier N, Champagne N, Stifani S, et al. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor RUNX2. Oncogene. 2002;21(17):2729–2740.
   PubMed Web of Science ®Google Scholar
• Xu J, Wu R-C, O’Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009;9(9):615–630.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189–195.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830–837.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–140.
   PubMed Web of Science ®Google Scholar
• Shigeno K, Yoshida H, Pan L, et al. Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett. 2004;213(1):11–20.
   PubMed Web of Science ®Google Scholar
• Inthal A, Zeitlhofer P, Zeginigg M, et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia. 2012;26(8):1797–1803.
   PubMed Web of Science ®Google Scholar
• Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–613.
   PubMed Web of Science ®Google Scholar
• Avantaggiati ML, Ogryzko V, Gardner K, et al. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997;89(7):1175–1184.
   PubMed Web of Science ®Google Scholar
• Wurm T, Wright DG, Polakowski N, et al. The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP. Nucleic Acids Res. 2012;40(13):5910–5925.
   PubMed Web of Science ®Google Scholar
• Clerc I, Polakowski N, Andre-Arpin C, et al. An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ. J Biol Chem. 2008;283(35):23903–23913.
   PubMed Web of Science ®Google Scholar
• Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001;92(12):1300–1304.
   PubMedGoogle Scholar
• Halkidou K, Gaughan L, Cook S, et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59(2):177–189.
   PubMed Web of Science ®Google Scholar
• Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;54(6):688–698.
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Byun D-S, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548–13558.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004;10(20):6962–6968.
   PubMed Web of Science ®Google Scholar
• Gloghini A, Buglio D, Khaskhely NM, et al. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol. 2009;147(4):515–525.
   PubMed Web of Science ®Google Scholar
• Lee H, Sengupta N, Villagra A, et al. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol. 2006;26(14):5259–5269.
   PubMed Web of Science ®Google Scholar
• Van Damme M, Crompot E, Meuleman N, et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics. 2012;7(12):1403–1412.
   PubMed Web of Science ®Google Scholar
• Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta. 2010;1799(10–12):717–725.
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu W-S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009;107(4):600–608.
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS, Sowa Y, Xu W-S, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005;102(3):673–678.
   PubMed Web of Science ®Google Scholar
• Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol. 2011;2011:1–9.
   Google Scholar
• Zhao Y, Tan J, Zhuang L, et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005;102(44):16090–16095.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Adachi M, Kawamura R, et al. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ. 2006;13(1):129–140.
   PubMed Web of Science ®Google Scholar
• Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 2003;10(4):400–403.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;7(4):437–443.
   PubMed Web of Science ®Google Scholar
• Woods DM, Sodre AL, Villagra A, et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015;3(12):1375–1385.
   PubMed Web of Science ®Google Scholar
• Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 2010;19(9):1049–1066.
   PubMed Web of Science ®Google Scholar
• Schneider-Stock R, Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs. 2007;10(8):557–561.
   PubMed Web of Science ®Google Scholar
• Suliman BA, Xu D, Williams BR. HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol. 2012;90(1):23–32.
   PubMed Web of Science ®Google Scholar
• Parmigiani RB, Xu WS, Venta-Perez G, et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A. 2008;105(28):9633–9638.
   PubMed Web of Science ®Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003;100(8):4389–4394.
   PubMed Web of Science ®Google Scholar
• Namdar M, Perez G, Ngo L, et al. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A. 2010;107(46):20003–20008.
   PubMed Web of Science ®Google Scholar
• Tang W, Luo T, Greenberg EF, et al. Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett. 2011;21(9):2601–2605.
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97(18):10014–10019.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115.
   PubMed Web of Science ®Google Scholar
• Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(6):412–416.
   PubMedGoogle Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198–1203.
   PubMed Web of Science ®Google Scholar
• Zhao W-L, Wang L, Liu Y-H, et al. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin’s B-lymphoma cells apoptosis. Exp Hematol. 2007;35(12):1801–1811.
   PubMed Web of Science ®Google Scholar
• Chen R, Frankel P, Popplewell L, et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015;100(3):357–362.
   PubMed Web of Science ®Google Scholar
• Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47(3):315–323.
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62(17):4916–4921.
   PubMed Web of Science ®Google Scholar
• Newbold A, Lindemann RK, Cluse LA, et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther. 2008;7(5):1066–1079.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–636.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.
   PubMed Web of Science ®Google Scholar
• Lunning MA, Ruan J, Nair S, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: phase I results. JCO. 2014;32:5s (suppl; abstract 8582).
   Google Scholar
• Holkova B, Kmieciak, M, Bose P, et al. Phase I study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma or cutaneous T-cell lymphoma: updated results. Blood. 2014;124:21.
   Web of Science ®Google Scholar
• Dai Chihara MP, Oki Y, Fayad L, et al. Phase I study of romidepsin in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2014;124(p):21.
   Google Scholar
• Fanale MA, Hagemeister, FB, Fayad L, et al. A phase I trial of alisertib plus romidepsin for relapsed/refractory aggresive B- and T- cell lymphomas. Blood. 2014;124:21.
   Web of Science ®Google Scholar
• Jehan Dupuis M, Morschhauser F, Ghesquieres H, et al. Final analysis of the RO-CHOP phase Ib/II study:romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL). Blood. 2014;124:21.
   Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811–819.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–2499.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Scotto L, Marchi E, et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010;16(2):554–565.
   PubMed Web of Science ®Google Scholar
• Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20):5506–5516.
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628–4635.
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500–4510.
   PubMed Web of Science ®Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386–394.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27(8):1628–1636.
   PubMed Web of Science ®Google Scholar
• Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53(9):1820–1823.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VT, Yoon -S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197–2203.
   PubMed Web of Science ®Google Scholar
• Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol. 2011;39(10):1007–1017.e1.
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003;63(13):3637–3645.
   PubMed Web of Science ®Google Scholar
• Buglio D, Younes A. Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs. 2010;28(Suppl 1):S21–7.
   Google Scholar
• Frys S, Simons Z, Hu Q, et al. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol. 2015;169(4):506–519.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–414.
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23(17):3912–3922.
   PubMed Web of Science ®Google Scholar
• Ning Z-Q, Li Z-B, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–909.
   PubMed Web of Science ®Google Scholar
• Gong K, Xie J, Yi H, et al. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443(3):735–746.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou J, Wang L, et al. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 2013;8(8):e70522.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Pan D-S, Shan S, et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483–491.
   PubMed Web of Science ®Google Scholar
• Dong M, Ning Z-Q, Xing P-Y, et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012;69(6):1413–1422.
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–1771.
   PubMed Web of Science ®Google Scholar
• Arrighetti N, Corno C, Gatti L. Drug combinations with HDAC inhibitors in antitumor therapy. Crit Rev Oncog. 2015;20(1–2):83–117.
   PubMedGoogle Scholar